Psoriasis (Auckland, N.Z.)最新文献

{"title":"Epidemiology of Hypertension in Psoriasis: An Analysis of Trends from 2006 to 2023.","authors":"Miao Zhang, Jia-Le Chen, Si-Wei Fan, Xiao-Ying Sun, Ya-Qiong Zhou, Ying Luo, Jiao Wang, Chun-Xiao Wang, Nai-Xuan Lin, Liu Liu, Xin Li","doi":"10.2147/PTT.S532112","DOIUrl":"10.2147/PTT.S532112","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis and hypertension (HTN) are known to be closely related. However, at present, no study has systematically examined the epidemiology of this disease pattern on a global scale.</p><p><strong>Methods: </strong>We examined six databases from their inception until November 1, 2023 and used the Agency for Healthcare Research and Quality and the Newcastle-Ottawa Scale to assess the quality of observational studies. Data analysis was conducted in R. Meta-regression, sensitivity, and subgroup analyses were used to evaluate interstudy heterogeneity. Egger's test and funnel plots were used to evaluate publication bias.</p><p><strong>Results: </strong>We reviewed 200 studies involving 15,010,888 patients. The overall prevalence of HTN among the patients with psoriasis was 32.22%. Overall, South America had the highest prevalence of hypertension among adult patients with psoriasis (52.36%), the three countries with the highest prevalence were Serbia, Singapore and Brazil. The prevalence of mild and severe psoriasis comorbid with HTN was 31.71% [95% CI: 24.40-40.05%] and 33.19% [95% CI: 27.17-39.81%], respectively. The prevalence of HTN in psoriasis vulgaris was 29.71% [95% CI: 25.10-35.15%], while that in psoriatic arthritis was 34.54% [95% CI: 31.27-38.14%].</p><p><strong>Conclusion: </strong>Patients with psoriatic arthritis are more predisposed to requiring hypertension risk screening than patients with psoriasis vulgaris. More population-based prospective observational studies are required to elucidate the mechanisms underlying the coexistence of hypertension in patients with psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"443-453"},"PeriodicalIF":5.2,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine Learning-Driven Prediction Models for Brodalumab Therapeutic Effect and Response Speed in Plaque Psoriasis.","authors":"Lu Peng, Liyang Wang, Ling Chen, Zhu Shen","doi":"10.2147/PTT.S531925","DOIUrl":"10.2147/PTT.S531925","url":null,"abstract":"<p><strong>Purpose: </strong>Biologic therapies have transformed plaque psoriasis treatment, but patient responses remain variable, neces+sitating machine prediction model for personalized therapy.</p><p><strong>Patients and methods: </strong>Transcriptomic and clinical data from moderate-to-severe psoriatic patient biopsies were sourced from GSE117468. Differential gene analysis identified Brodalumab treatment-associated genes. Lasso regression selected response-related genes, and LightGBM was used to build machine learning models. Model robustness was assessed using five-fold cross-validation.</p><p><strong>Results: </strong>Biopsies (n=491) from 116 patients' lesional (LS) and non-lesional (NL) tissues were analyzed, divided into Brodalumab (140 mg or 210 mg) and placebo groups. Responders were defined as achieving ≥75% improvement in Psoriasis Area and Severity Index at week 12. Lasso identified genes from classical psoriasis pathways (IL-17, PPAR signaling, HLA-D alleles) and novel targets (WIF1, SLC44A5, LOC441528, SAA1). Six LightGBM models were trained to predict 12-week treatment response and 4-week response speed using LS, NL, and combined (LS_&_NL) data. LS_&_NL models showed superior performance, achieving AUC-ROC values of 95.14% (140 mg) and 92.83% (210 mg) for 12-week response prediction and 98.70% (140 mg) and 97.51% (210 mg) for 4-week response speed prediction.</p><p><strong>Conclusion: </strong>These models provide robust tools for predicting Brodalumab response, supporting precision medicine and optimizing resource allocation in plaque psoriasis management.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"429-442"},"PeriodicalIF":5.2,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12378525/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis.","authors":"Paolo Gisondi, Francesco Bellinato, Tea Curic, Giampiero Girolomoni","doi":"10.2147/PTT.S510156","DOIUrl":"10.2147/PTT.S510156","url":null,"abstract":"<p><p>Psoriasis is an immune-mediated chronic inflammatory skin disease affecting over 60 million adults and children worldwide and can occur at any age, from childhood to adulthood. If the patient has a diffuse form of psoriasis, affecting more than ten percent of the body surface, or involving sensitive areas such as the face, scalp, nails, and/or palmoplantar region, he or she is a candidate for systemic therapy. Currently, several drugs are approved for the treatment of moderate to severe chronic plaque psoriasis in Europe and US. These are classified into conventional systemics, biologics, and small molecules. These immunomodulatory agents are available in different forms of administration, such as oral, subcutaneous, and intravenous. Novel treatments, including biologics and small molecules, can provide reliable disease control with a good safety profile even in the long term and have greatly improved the quality of life for many patients. Nevertheless, biologics can be expensive, placing a significant burden on national healthcare systems and creating a barrier to access for patients in need of these life-changing therapies. A biosimilar drug is a biologic medical product that is highly similar to an already approved reference biologic drug (also known as the originator). Biosimilars have no clinically meaningful differences in terms of safety, purity, and efficacy compared to the reference product. Biosimilar drugs have been on the market-and therefore in clinical practice-for several years now, helping to overcome these challenges. Biosimilars have the potential to improve access to biologic therapies for psoriasis while reducing healthcare costs. The aim of this narrative review is to describe biosimilars and the potential cost-saving benefits their use can offer. In this review, we will discuss adalimumab, infliximab, etanercept, and ustekinumab, as well as their corresponding biosimilars.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"401-410"},"PeriodicalIF":5.2,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome.","authors":"Lipeng Tang, Huichang Bi, Kangguang Lin, Yisi Chen, Haiyan Xian, Yuan Li, Hesong Xie, Guangjuan Zheng, Peng Wang, Yonggen Chen, Biying Yang, Yaqian Tan, Qi Song, Maojie Wang, Guanzhuo Li, Jiameng Chang, Yuanjun Guan, Kwok-Fai So, Chuanjian Lu","doi":"10.2147/PTT.S535900","DOIUrl":"10.2147/PTT.S535900","url":null,"abstract":"<p><p>Psoriasis, a common chronic inflammatory skin disease affecting approximately 2-3% of the global population, frequently co-occurs with depression. This highly prevalent comorbidity significantly impairs patients' quality of life. Despite the substantial physical and mental health burden imposed by psoriatic depression, the underlying pathophysiological mechanisms connecting psoriasis and depression remain poorly understood. In this review, we explored several pathological processes that may contribute to psoriasis-associated depression, including immune cells dysregulations, hormones imbalances, hypothalamic-pituitary-adrenal (HPA) axis dysfunctions, neuropeptides expression abnormalities, and gut dysbiosis. The primary purpose of this review was to present a comprehensive overview of the pathogenic mechanisms linking psoriasis and depression. These insights may guide trans-disciplinary interventions aimed at both skin and mood symptoms.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"411-428"},"PeriodicalIF":5.2,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12372838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Effect of Plasma Fatty Acid Profiles on Psoriasis Risk: Genetic Evidence from a Mendelian Randomization Study.","authors":"Lei Yao, Xi Wang, Dongmei Lu, Suyan Tian","doi":"10.2147/PTT.S538518","DOIUrl":"10.2147/PTT.S538518","url":null,"abstract":"<p><strong>Introduction: </strong>Emerging evidence indicates that omega-3 fatty acids from fish oil may serve as beneficial dietary supplements for psoriasis management. Clinical observations demonstrate a significant association between psoriasis improvement and increased docosahexaenoic acid (DHA) levels. However, the causal relationship between fatty acids and psoriasis risk requires further investigation.</p><p><strong>Methods: </strong>Using summary-level genome-wide association study (GWAS) data, we applied univariable (UVMR), reverse, and multivariable (MVMR) Mendelian randomization analyses to assess causal effects of multiple fatty acids-including polyunsaturated (PUFA), saturated (SFA), monounsaturated (MUFA), omega-3/6 fatty acids, DHA, eicosapentaenoate (EPA) and docosapentaenoate (DPA)-on psoriasis risk.</p><p><strong>Results: </strong>The analysis revealed that higher circulating levels of omega-3 fatty acids were significantly associated with a reduced risk of psoriasis development (UVMR: OR = 0.900, p = 0.022; MVMR: OR = 0.862, p = 0.007). Sensitivity analyses supported the robustness of this causal relationship, with consistent effects across multiple MR methods. Notably, DHA (UVMR: OR = 0.788, p = 0.006; MVMR: OR = 0.856, p = 0.021) drove this inverse association, while EPA and DPA showed marginal contributions.</p><p><strong>Conclusion: </strong>This study provides valuable insights for targeted nutritional strategies to prevent and manage psoriasis, but further validation is needed.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"389-399"},"PeriodicalIF":5.2,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144981873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Skin Clearance: Personalized Strategies for DLQI Improvement in Psoriasis -Insights From a Shanghai Prospective Cohort.","authors":"Xin Ma, Quanruo Xu, Le Kuai, Fanlingzi Shen, Zhen Duan, Xiangjin Gao, Rui Zhang, Ruiping Wang","doi":"10.2147/PTT.S534881","DOIUrl":"10.2147/PTT.S534881","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic immune-mediated disease that significantly impacts patients clinically and psychologically. Physician-assessed severity measures, including Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Physician Global Assessment (PGA), often fail to capture patient-reported outcomes, particularly when clinical improvement and perceived quality-of-life gains are misaligned.</p><p><strong>Purpose: </strong>To clarify the association between clinical improvements and Dermatology Life Quality Index (DLQI) outcomes, identify predictors of substantial DLQI improvement (≥90% reduction), and explore reasons for suboptimal DLQI responses in patients achieving skin clearance.</p><p><strong>Methods: </strong>In this 12-week prospective study, 551 psoriasis patients were enrolled at Shanghai Skin Diseases Hospital. Data on demographics, clinical severity (PASI, BSA, and PGA), DLQI scores, and treatment modalities were collected. Logistic regression analyses were employed to assess the dose-response relationships between improvements in clinical parameters and DLQI reduction, and to identify factors of suboptimal DLQI improvement among patients achieving significant skin clearance.</p><p><strong>Results: </strong>Median DLQI improved significantly (8.0 to 3.0) at week 12, with 24.1% of patients achieving ≥90% DLQI reduction. Strong dose-response associations existed between clinical severity improvements (PASI, BSA, PGA) and DLQI gains. PASI₇₅ responders were significantly more likely to achieve substantial DLQI improvement (OR = 2.48, 95% CI: 1.51-4.07). However, only 33.3% of PASI₇₅ achievers reached ≥90% DLQI improvement. Early clinical response (as early as week 4) strongly predicted superior DLQI outcomes. Female sex, older age, lower baseline DLQI scores, and shorter disease duration were associated with achieving high skin clearance but suboptimal DLQI improvement.</p><p><strong>Conclusion: </strong>Early clinical response effectively predicts substantial DLQI improvement, whereas demographic and disease-related factors help identify patients at risk for suboptimal quality-of-life gains despite significant skin clearance. These insights support personalized therapeutic strategies aimed at improving patient satisfaction beyond skin clearance alone.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"373-387"},"PeriodicalIF":5.2,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12358121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses.","authors":"Bowen Dai, Ye Tang, Bin Zhang, Guangyao Xu, Yanan Zhang, Kan Ze","doi":"10.2147/PTT.S535434","DOIUrl":"10.2147/PTT.S535434","url":null,"abstract":"<p><strong>Background: </strong>Genetic susceptibility to psoriasis involves multiple loci, including TYK2 (Tyrosine Kinase 2), which is associated with various autoimmune diseases. However, its specific role and mechanisms in psoriasis remain unclear. This study aimed to identify psoriasis-associated proteins using Summary-based Mendelian Randomization (SMR) and to explore their regulatory mechanisms.</p><p><strong>Methods: </strong>SMR analysis integrating pQTL data was conducted to identify proteins linked to psoriasis, revealing ICAM1 (Intercellular Adhesion Molecule 1) as a potential pathogenic factor. A key SNP, rs34536443 (P1104A), located in TYK2, was found to regulate ICAM1. To assess its function, THP-1 cells carrying the TYK2-P1104A mutation were generated, and ICAM1 and cytokine expression were analyzed following LPS stimulation. The effect of the TYK2 inhibitor Deucravacitinib was tested in an imiquimod (IMQ)-induced psoriasis mouse model.</p><p><strong>Results: </strong>SMR identified ICAM1 as a causal protein for psoriasis, regulated by the TYK2 SNP rs34536443. In TYK2-P1104A mutant THP-1 cells, LPS-induced ICAM1 expression was significantly reduced, with ICAM5 unaffected. The mutation also suppressed IL-1β, TNF-α, IL-6, and IL-18 expression, suggesting anti-inflammatory effects. Single-cell RNA-seq revealed enrichment of TYK2, ICAM1, and ICAM5 in dendritic cells and monocytes. In vivo, Deucravacitinib significantly downregulated ICAM1 in the IMQ-induced psoriasis model, with minimal effect on ICAM5.</p><p><strong>Conclusion: </strong>This study identifies ICAM1 as a key mediator in psoriasis via SMR analysis and implicates the TYK2 SNP rs34536443 in its regulation. The TYK2-P1104A variant attenuates ICAM1 and cytokine expression, and Deucravacitinib downregulates ICAM1 in vivo. These findings provide mechanistic insights into the TYK2-ICAM1 axis and support the therapeutic potential of TYK2 inhibitors for psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"361-372"},"PeriodicalIF":5.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bimekizumab: The First FDA-Approved Dual IL-17A/IL-17F Inhibitor for Plaque Psoriasis - A Comprehensive Literature Review.","authors":"Sukainah Ahmed Al Alshaikh, Zahra Mohammad Almarhoon, Hisham Momattin, Mahdi Aleid, Zahra H Almousa, Ali Kamal Alqaisum, Fatimah Ismail Mobarki, Sarah Aon Almakki, Hamzah Alturfi, Kouther Jamil Almajed","doi":"10.2147/PTT.S544166","DOIUrl":"10.2147/PTT.S544166","url":null,"abstract":"<p><p>Psoriasis is a chronic inflammatory immune-mediated disease that affects 1-3% of the worldwide population. It is now known that interleukin IL-17F and IL-17A have a role in the pathophysiology of immune-mediated inflammatory disorders, such as psoriasis. According to recent data, neutralizing IL-17A and -17F together may be more effective than neutralizing IL-17A alone in treating psoriasis. Bimekizumab is a humanized IgG1 monoclonal antibody that selectively binds and diminishes the biological functions of both IL-17A and -17F. Current biologics for treating psoriasis lack complete skin clearance and reliable quick response. Bimekizumab's efficacy was evaluated in four randomized controlled trials involving around 2,200 patients with plaque psoriasis. The results showed that bimekizumab outperformed placebo, adalimumab, secukinumab, and ustekinumab, with higher response rates for both PASI 90 and PASI 100 at 16 weeks. Furthermore, Bimekizumab has shown superiority in direct comparative clinical studies (RCTs) performed. When compared to other biologics, Bimekizumab has shown a more rapid onset in terms of rapid response and better efficacy with a comparable safety profile as the most frequent adverse events include oral candidiasis, upper respiratory tract infections, and nasopharyngitis. These features of Bimekizumab provide advantages for the patients in term of better efficacy with rapid response and safe profile which ultimately affect the selection and treatment algorithm for management of plaque psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"351-360"},"PeriodicalIF":5.2,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization and Costs of Laboratory Monitoring in Biological and Non-Biological Psoriasis Treatment - Large-Scale Claims Data Analysis.","authors":"Jan Nicolai Wagner, Kristina Hagenström, Katharina Sophia Müller, Brigitte Stephan, Matthias Augustin, Ralph von Kiedrowski","doi":"10.2147/PTT.S531836","DOIUrl":"10.2147/PTT.S531836","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis vulgaris is a chronic systemic inflammatory disease that imposes a significant physical, emotional, and social burden on affected individuals. There is a growing recognition of the importance of comprehensive monitoring and management to optimize treatment outcomes, particularly with the advent of advanced systemic therapies. This study aims to characterize the prevalence of laboratory monitoring and associated costs in persons with psoriasis undergoing systemic treatment. A specific focus was placed on the differences by treatment modality, patient characteristics, and economic burden to the payers.</p><p><strong>Patients and methods: </strong>A retrospective longitudinal analysis was conducted using German health insurance data from the DAK-Gesundheit. The study population included persons diagnosed with psoriasis who received systemic therapies between 2016 and 2020. Laboratory service utilization and costs were assessed during the initiation and course of treatment, factoring in demographic parameters and comorbidities.</p><p><strong>Results: </strong>Among 62,063 persons with psoriasis, 8018 (12.9%) were identified as having received systemic treatment, which of 92.5% utilized at least one laboratory service. The average annual laboratory monitoring cost per person was higher for those on biologic therapies (57.88 €) compared to systemic treatments (23.70 €). Laboratory service utilization and costs were associated with the comorbidity index (CCI) and age.</p><p><strong>Conclusion: </strong>Biologic therapies for psoriasis induce considerably higher monitoring costs than non-biological systemic drugs. Age and CCI were main predictors for higher utilization of laboratory services, indicating a medical rationale to perform more lab screenings in risk groups for safety events. The laboratory costs add to the higher drug costs of biologicals but need to be related to the benefits from treatment. Furthermore, the monitoring costs are far lower than the drug costs and thus may not be major decision drivers.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"327-338"},"PeriodicalIF":5.2,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years.","authors":"Luca Mastorino, Paolo Dapavo, Martina Burlando, Paolo Gisondi, Carlo Alberto Maronese, Angelo Ruggiero, Marco Galluzzo, Maria Carla Pisani, Lidia Sacchelli, Giacomo Caldarola, Gianluca Avallone, Angelo Valerio Marzano, Matteo Megna, Elena Campione, Francesco Loconsole, Federico Bardazzi, Clara De Simone, Pietro Quaglino, Simone Ribero","doi":"10.2147/PTT.S525256","DOIUrl":"10.2147/PTT.S525256","url":null,"abstract":"<p><strong>Purpose: </strong>Elderly patients with age ≥65 years represent an increasing percentage of the population with moderate-severe psoriasis. The definition of \"frail elderly\" is not easily framed, generally meaning a patient with unstable homeostasis. To date, there is no study in the literature examining possible differences between frail and non-frail elderly with psoriasis being treated with tildrakizumab.</p><p><strong>Patients and methods: </strong>The present multicentre retrospective study evaluated the effectiveness, drug survival and safety up to 2 years of treatment with tildrakizumab in the elderly (≥65 years) comparing frail and non-frail patients. Frail patients were defined as those with: i) 2 major comorbidities, or 1 major comorbidity and low economic level ii) and/or 2 of the following 5 parameters: weight loss, weakness, sluggishness, low activity level, and exhaustion.</p><p><strong>Results: </strong>A total of 217 patients aged ≥65 years were enrolled, of whom 89 (41%) were grouped in the frail patient category. In the entire population, 2-year drug survival was ≥80%, and PASI 90 and ≤2 was achieved in 75% and 87.5% of patients, respectively. No difference in effectiveness or safety was found between frail and non-frail populations. Adjusting for baseline characteristics at Cox-regression, frail patients did not show a greater risk of discontinuation (HR 0.51, p=0.091).</p><p><strong>Conclusion: </strong>Tildrakizumab showed good safety and effectiveness at 2 years in the elderly population with or without frailty, confirming it as a possible treatment of choice in psoriatic patients with significant comorbidities and older frail patients who deserve systemic treatments.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"339-350"},"PeriodicalIF":5.2,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144823303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}